Several recent developments point to Kigali’s growing role in Africa’s biopharmaceutical landscape. Rwanda has positioned itself as a strategic hub through a combination of investment in scientific ...

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...

For the study, published early Friday in the journal Kidney Medicine, researchers looked at about 3,500 patients who were hospitalized with COVID-19 between March 1, 2020, and March 30, 2022. Of ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately $1.25bn. The deal is aimed at strengthening BioNTech’s research, ...

Skadden is advising CureVac N.V. on its definitive purchase agreement with BioNTech SE, pursuant to which BioNTech intends to acquire all of the shares of CureVac. Under the terms of the purchase ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals Stock Markets Published 06/12/2025, 10:00 AM Updated 06/12/2025, 02:36 PM ...

BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will ...